Next 10 |
home / stock / bhc / bhc articles
Risk appetite is surging again Thursday on Wall Street, with investors welcoming the Federal Reserve’s decision to keep rates unchanged and F...
After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick...
The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, d...
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bausch Health Companies Inc. ("Baus...
U.S. stocks traded mostly higher on Wednesday. Here are some big stocks recording gains in today’s session. Steelcase Inc. (NYSE: SCS) share...
NEW YORK, Sept. 17, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bausch...
SAN DIEGO, Sept. 16, 2023 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Bausch Health Compa...
NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Attention Bausch Health Companies Inc. ("Bausch") (NYSE:BHC) shareholders: The Law Offices ...
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bausch ...
News, Short Squeeze, Breakout and More Instantly...
Bausch Health Companies Inc. Company Name:
BHC Stock Symbol:
NYSE Market:
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business up...
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceutica...
2024-04-11 13:00:03 ET Glen Santangelo from Jefferies issued a price target of $16.00 for BHC on 2024-04-11 11:29:00. The adjusted price target was set to $16.00. At the time of the announcement, BHC was trading at $9.275. The overall price target consensus is at $9.00 w...